Amplified genes as therapeutic targets in cancer

Drug Discovery Today: TARGETS

Volumn 2, Issue 4, 2003, Pages 147-153

  Basik, Mark ^a   Caplen, Natasha J ^b   Kallioniemi, Olli P ^c   Mousses, Spyro ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CISPLATIN; COMPLEMENTARY DNA; DELETED IN COLORECTAL CANCER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HORMONE; NUCLEIC ACID; PACLITAXEL; PLATINUM; RAS PROTEIN; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA MICROARRAY; DRUG APPROVAL; DRUG EFFICACY; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RNA INTERFERENCE; VALIDATION PROCESS;

EID: 15944426384     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1477-3627(03)02351-1     Document Type: Review

References (53)

1. Mertens, F. et al. (1997) Chromosomal imbalance maps of malignant solid tumors. A cytogenetic survey of 3185 neoplasms. Cancer Res. 57, 2765-2780
2. Schröck, E. et al. (1996) Multicolor spectral karyotyping of human chromosomes. Science 273, 494-497
3. Pandis, N. et al. (1995) Chromosome analysis of 9 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer 12, 173-185
4. Slamon, D.J. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 12, 707-712
5. Cobleigh, M.A. et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648
6. Slamon, D.J. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med. 15, 783-792
7. Kallioniemi, A. et al. (1994) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. U. S. A. 91, 2156-2160
8. Nakao, K. et al. (1998) Genetic changes in primary colorectal cancer by comparative genomic hybridization. Surg. Today 28, 567-569
9. Platzer, P. et al. (2002) Silence of chromosomal amplifications in colon cancer. Cancer Res. 62, 1134-1138
10. Pinkel, D. et al. (1998) High resolution analysis of DNA copynumber variation using comparative genomic hybridization to microarrays. Nat. Genet. 20, 207-211
11. DeRisi, J. et al. (1996) Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat. Genet. 14, 457-460
12. Pollack, J.R. et al. (1999) Genome-wide analysis of DNA copy number changes using cDNA microarrays. Nat. Genet. 23, 41-46
13. Hyman, E. et al. (2002) Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 1, 6240-6245
14. Pollack, J.R. et al. (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. U. S. A. 1, 12963-12968
15. Kononen, J. et al. (1998) Tissue microarray for high throughput molecular profiling of tumor specimens. Nat. Med. 4, 844-847
16. Kallioniemi, O.P. et al. (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 10, 657-662
17. Camp, R.L. et al. (2000) Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80, 1943-1949
18. Hoos, A. and Cordon-Cardo, C. (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab. Invest. 81, 1331-1338
19. Torhorst, J. et al. (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159, 2249-2256
20. Caplen, N.J. et al. (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. U. S. A. 98, 9742-9747
21. Elbashir, S.M. et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498
22. Elbashir, S.M. et al. (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200
23. Hammond, S.M. et al. (2001) Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293, 1146-1150
24. Liu, J. et al. (2002) Mediation of the DCC apoptotic signal by DIP13 alpha. J. Biol. Chem. 277, 26281-26285
25. Varambally, S. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629
26. Frankish, H. (2003) Consortium uses RNAi to uncover genes' function. Lancet 361, 584
27. Hannon, G.J. (2002) RNA interference. Nature 418, 244-251
28. Paddison, R.J. and Hannon, G.J. (2002) RNA interference: the new somatic cell genetics? Cancer Cell 2, 17-23
29. Nicholson, R.I. et al. (2001) EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl. 4), S9-S15
30. Shawver, L.K. et al. (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123
31. Schiller, J.H. (2003) New directions for ZD1839 in the treatment of solid tumors. Semin. Oncol. 30(Suppl. 1), 49-55
32. Ciardiello, F. et al. (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063
33. Kris, M.G. et al. (2002) A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NCSLC) patients who had failed platinum and docetazel-base regimens (IEAL20). Proc. Am. Soc. Clin. Oncol. 21, 292a
34. Fukuuoka, M. et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 21, 2237-2246
35. Burton, A. (2002) What went wrong with Iressa? Lancet Oncol. 3, 708
36. Dyer, O. (2003) FDA announces fast track approval of new drug for lung cancer. BMJ 326, 1004
37. Harries, M. and Smith, I. (2002) The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer 9, 75-85
38. Slamon, D.J. et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 9, 177-182
39. Vogel, C.L. et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 1. 719-726
40. Paterson, B.M. et al. (1977) Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. U. S. A. 74, 4370-4374
41. Stephenson, M.L. and Zamecnik, P.C. (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U. S. A. 75, 285-288
42. Opalinska, J.B. and Gewirtz, A.M. (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514
43. Carmell, M. A. et al. (2003) Germline transmission of RNAi in mice. Nat. Struct. Biol. 10, 91-92
44. Hemann, M.T. et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33, 396-400
45. Lewis, D.L. et al. (2002) Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32, 107-108
46. McCaffrey, A.P. et al. (2002) RNA interference in adult mice. Nature 418, 38-39
47. Rubinson, D.A. et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33, 401-406
48. Tiscornia, G. et al. (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. U. S. A. 100, 1844-1848
49. Xia, H. et al. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006-1010
50. Brummelkamp, T.R. et al. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247
51. Scherr, M. et al. (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101, 1566-1569
52. Wilda, M. et al. (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21, 5716-5724
53. Chen, Y. et al. (2002) Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 18, 1207-1215